<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03404336</url>
  </required_header>
  <id_info>
    <org_study_id>WBT in MIG</org_study_id>
    <nct_id>NCT03404336</nct_id>
  </id_info>
  <brief_title>Study on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Control Therapy</brief_title>
  <official_title>Pilot Randomized Controlled Trial to Evaluate the Efficacy of Well-Being Therapy vs a Control Condition in Chronic Migraine Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florence</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florence</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic migraine is a disabling type of migraine and is often resistant to treatment.
      Non-pharmacological interventions have been investigated as potential treatment although,
      unfortunately, the literature on their efficacy is poor and showed mixed results. Well-Being
      Therapy (WBT) is a brief psychotherapy which has shown efficacy in decreasing the relapse
      rates of depression in adults, in generalized anxiety disorder and in cyclothymia. It can be
      implemented to empower psychological well-being. The aim of the present study is to test the
      efficacy of WBT in a sample of patients with chronic migraine to verify if it reduces the
      disability due to migraine and distress, it increases the psychological well-being as well as
      the level of euthymia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic migraine is a disabling type of migraine and is often resistant to treatment.
      Non-pharmacological interventions have been investigated as potential treatment although,
      unfortunately, the literature on their efficacy is poor and showed mixed results. The
      psychological interventions tested up to now are the Acceptance and Commitment Therapy and
      the Mindfulness. Well-Being Therapy (WBT) is a brief psychotherapy which has been manualized
      in 2016 and has shown efficacy in randomized clinical trials. It showed to be effective in
      decreasing the relapse rates of depression in adults, it showed to be effective in
      generalized anxiety disorder and in cyclothymia. Thus, psychological well-being can be
      implemented and empowered via a specific psychotherapy and this implementation might produce
      a protecting effect, thus favoring prevention. The aim of the present study is to test the
      efficacy of WBT in a sample of patients with chronic migraine. First the efficacy of WBT will
      be verified in terms of disability due to migraine. Then, the efficacy of WBT will be
      measured in terms of psychological well-being, euthymia, and distress. For this purpose, 30
      chromic migraine outpatients will be enrolled in a randomized, controlled, open clinical
      study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a pilot study, designed as a randomized (1:1) controlled trial, comparing WBT vs a control condition. The patients will receive a baseline assessment to confirm the diagnosis of chronic migraine, then socio-demographic information, information on pharmacological/non-pharmacological treatments, on the history of medical diseases and on the psychological status will be collected as well as the number of migraine attacks per month, the duration of migraine attacks, the occurrence of migraine exclusively with menses, and the level of disability related to migraine. Thereafter, the subjects will be randomly assigned to WBT or to a control condition. The subjects will be re-assessed at the end of session 4, 8 of treatment, at 3-month and 6-month follow-ups.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants will not be informed if they will receive the WBT or the control condition. Of course, after the end of the study they will receive this information and they will be told why they were blind.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>disability due to migraine</measure>
    <time_frame>from baseline to 3-month follow up</time_frame>
    <description>level of disability due to migraine assessed via the Migraine Disability Assessment Score (score from 0 to &gt;21, for total score &gt; 6 disability is clinically relevant)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>frequency of migraine attacks</measure>
    <time_frame>from baseline to 3-month follow up</time_frame>
    <description>frequency of migraine attacks assessed via a daily self-report headache diary (higher the frequency, higher the severity of migraine)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>duration of migraine attacks</measure>
    <time_frame>from baseline to 3-month follow up</time_frame>
    <description>duration of migraine attacks assessed via a daily self-report headache diary (higher the duration, higher the severity of migraine)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>intensity of migraine attacks</measure>
    <time_frame>from baseline to 3-month follow up</time_frame>
    <description>intensity of migraine attacks assessed via a daily self-report headache diary (higher the intensity, higher the severity of migraine)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>level of anxiety and depression</measure>
    <time_frame>from baseline to 3-month follow up</time_frame>
    <description>the level of anxiety and depression will be assessed via the Symptom Questionnaire (total score from 0 to 92, higher is the total score and worse is the symptomatology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of psychological well-being</measure>
    <time_frame>from baseline to 3-month follow up</time_frame>
    <description>assessed via the World Health Organization-Five Well-Being Index (WHO 5) (total score from 0 to 25, higher total score means higher quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of psychological well-being</measure>
    <time_frame>from baseline to 3-month follow up</time_frame>
    <description>assessed via Psychological Well-Being Questionnaire (PWB) (total score from 84 to 504, higher score corresponds to higher psychological well-being)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the level of euthymia</measure>
    <time_frame>from baseline to 3-month follow up</time_frame>
    <description>the level of euthymia will be assessed via the euthymia scale (total score from 0 to 10, higher score corresponds to higher level of euthymia)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Migraine</condition>
  <arm_group>
    <arm_group_label>Well-being therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WBT will be used as the only non-pharmacological therapeutic strategy and 8 sessions will be delivered every other week with a duration of 60 minutes each. The manualized WBT will be used (Fava, 2016). Thus, the initial phase will be concerned with self-observation of psychological well-being. Once the instances of well-being will be properly recognized, the patient will be encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of well-being (intermediate phase). The final part will involve cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control condition</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control condition will include 8 be-weekly sessions based on Lifestyle and well-being National Institute for health and Care Excellence (NICE) guidelines (https://www.nice.org.uk/guidance/lifestyle-and-wellbeing) and on World Health Organization 12 steps to healthy eating (http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle). These sessions will inform participants about well-being and which lifestyles can influence it.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Well-Being Therapy</intervention_name>
    <description>Session 1: identifying and setting episodes of wellbeing into situational context. Session 2: identifying interfering thoughts and behaviors. Session 3: illustrating autonomy, reflecting and practicing it. Session 4: illustrating environmental mastery, reflecting and practicing it. Session 5: illustrating positive relations with others, reflecting and practicing it. Session 6: illustrating personal growth, reflecting and practicing it. Session 7: illustrating self-acceptance, reflecting and practicing it. Session 8: illustrating purpose in life, reflecting and practicing it.</description>
    <arm_group_label>Well-being therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control condition</intervention_name>
    <description>Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drugs misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.</description>
    <arm_group_label>Control condition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. able and interested in participating to the present research project, as proved by
             signed Informed consent;

          2. 18-65 years of age;

          3. Italian mother tongue;

          4. diagnosis of chronic migraine according to the International Classification of
             Headache Disorders. Thus, presenting specific features (i.e., unilateral and pulsating
             pain of moderate or severe intensity, which is aggravated or precipitated by routine
             physical activities and is combined with nausea and/or vomiting, photophobia, and
             phonophobia) and migraine headache on â‰¥ 15 days per month;

          5. headache chronicity for a minimum of 1 year and pattern of headache symptoms stable
             for a period of at least 6 months;

          6. no pharmacological therapy or dietary supplements use for chronic migraine OR
             pharmacological therapy/dietary supplement use for chronic migraine stable since at
             least 3 months;

          7. psychotropic medication allowed only if stable since at least three months.

        Exclusion criteria:

          1. diagnosis of medication overuse headache;

          2. co-occurrence of psychiatric disorder(s) according to the Diagnostic and Statistical
             Manual of mental disorders (DSM) 5th edition as diagnosed via the MINI International
             Neuropsychiatric Interview;

          3. co-occurrence of chronic unstable medical conditions;

          4. being pregnant or lactating;

          5. under exogeneous hormones treatment (i.e., hormonal contraceptives, postmenopausal
             hormone therapy);

          6. any other condition that, according to the Investigators' opinion, may alter the
             ability of the patient to follow study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fiammetta COSCI, Prof.</last_name>
    <phone>0552755066</phone>
    <phone_ext>0039</phone_ext>
    <email>fiammetta.cosci@unifi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fiammetta COSCI</name>
      <address>
        <city>Florence</city>
        <zip>50135</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fiammetta COSCI, MD, PhD</last_name>
      <phone>0552755066</phone>
      <phone_ext>0039</phone_ext>
      <email>fiammetta.cosci@unifi.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2018</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Florence</investigator_affiliation>
    <investigator_full_name>Fiammetta Cosci</investigator_full_name>
    <investigator_title>Associate Professor in Clinical Psychology</investigator_title>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>chronic</keyword>
  <keyword>well-being therapy</keyword>
  <keyword>psychotherapy</keyword>
  <keyword>therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

